Syndax Pharmaceuticals Inc financial data

Symbol
SNDX on Nasdaq
Industry
Pharmaceutical Preparations
Location
35 Gatehouse Drive, Building D, Floor 3, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 5, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 899 % -36.2%
Debt-to-equity 11.5 % +51.9%
Return On Equity -64.3 % -51.8%
Return On Assets -57.7 % -46.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 85.1M shares +22.5%
Common Stock, Shares, Outstanding 85.6M shares +22.9%
Entity Public Float 1.08B USD +30.1%
Common Stock, Value, Issued 9K USD +28.6%
Weighted Average Number of Shares Outstanding, Basic 85.4M shares +22.3%
Weighted Average Number of Shares Outstanding, Diluted 85.4M shares +22.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 12.5M USD
Research and Development Expense 231M USD +65.5%
General and Administrative Expense 31.1M USD +80.1%
Operating Income (Loss) -321M USD -65.5%
Nonoperating Income (Expense) 24.2M USD +38.2%
Net Income (Loss) Attributable to Parent -297M USD -68.7%
Earnings Per Share, Basic -3.65 USD/shares -40.9%
Earnings Per Share, Diluted -3.65 USD/shares -40.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 133M USD +40.7%
Other Assets, Current 3.51M USD
Assets, Current 415M USD +8.88%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 756K USD -56.3%
Other Assets, Noncurrent 0 USD -100%
Assets 426M USD +6.66%
Accounts Payable, Current 4.9M USD -19%
Employee-related Liabilities, Current 11.6M USD +46.3%
Liabilities, Current 59.4M USD +51.6%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 59.4M USD +48.3%
Retained Earnings (Accumulated Deficit) -1.13B USD -35.8%
Stockholders' Equity Attributable to Parent 366M USD +2.02%
Liabilities and Equity 426M USD +6.66%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -83.5M USD -113%
Net Cash Provided by (Used in) Financing Activities 2.17M USD -12.4%
Net Cash Provided by (Used in) Investing Activities -99.4M USD -599%
Common Stock, Shares Authorized 200M shares +100%
Common Stock, Shares, Issued 85.6M shares +22.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -181M USD -974%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 206M USD +54.8%
Deferred Tax Assets, Gross 206M USD +54.8%
Operating Lease, Liability 1.61M USD +41.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -296M USD -69.3%
Lessee, Operating Lease, Liability, to be Paid 1.8M USD +33.4%
Property, Plant and Equipment, Gross 419K USD 0%
Operating Lease, Liability, Current 842K USD -15.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 606K USD +3.59%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.2M USD +111%
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 189K USD -9.14%
Deferred Tax Assets, Operating Loss Carryforwards 32.7M USD +38.1%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 143K USD 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 39.1M USD +45.4%
Interest Expense 233K USD -87.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%